Cargando…
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anap...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601201/ https://www.ncbi.nlm.nih.gov/pubmed/36290895 http://dx.doi.org/10.3390/curroncol29100618 |